Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas

Open access
Lassaletta, Alvaro, Zapotocky, Michal, Mistry, Matthew, Ramaswamy, Vijay, Honnorat, Marion, Krishnatry, Rahul, Guerreiro Stucklin, Ana, Zhukova, Nataliya, Arnoldo, Anthony, Ryall, Scott, Ling, Catriona, McKeown, Tara, Loukides, Jim, Cruz, Ofelia, de Torres, Carmen, Ho, Cheng-Ying, Packer, Roger J., Tatevossian, Ruth, Qaddoumi, Ibrahim, Harreld, Julie H., Dalton, James D., Mulcahy-Levy, Jean, Foreman, Nicholas, Karajannis, Matthias A., Wang, Shiyang, Snuderl, Matija, Nageswara Rao, Amulya, Giannini, Caterina, Kieran, Mark, Ligon, Keith L., Garre, Maria Luisa, Nozza, Paolo, Mascelli, Samantha, Raso, Alessandro, Mueller, Sabine, Nicolaides, Theodore, Silva, Karen, Perbet, Romain, Vasiljevic, Alexandre, Faure Conter, Cécile, Frappaz, Didier, Leary, Sarah, Crane, Courtney, Chan, Aden, Ng, Ho-Keung, Shi, Zhi-Feng, Mao, Ying, Finch, Elizabeth, Eisenstat, David, Wilson, Bev, Carret, Anne Sophie, Hauser, Peter, Sumerauer, David, Krskova, Lenka, Larouche, Valerie, Fleming, Adam, Zelcer, Shayna, Jabado, Nada, Rutka, James T., Dirks, Peter, Taylor, Michael D., Chen, Shiyi, Bartels, Ute, Huang, Annie, Ellison, David W., Bouffet, Eric, Hawkins, Cynthia, Tabori, Uri·2017·Journal of Clinical Oncology

Abstract

Purpose: BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods: A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results: BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.71.8726

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 349

Metadata

Authors
Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., Ling, C., McKeown, T., Loukides, J., Cruz, O., de Torres, C., Ho, C.-Y., Packer, R. J., Tatevossian, R., Qaddoumi, I., Harreld, J. H., Dalton, J. D., Mulcahy-Levy, J., Foreman, N., Karajannis, M. A., Wang, S., Snuderl, M., Nageswara Rao, A., Giannini, C., Kieran, M., Ligon, K. L., Garre, M. L., Nozza, P., Mascelli, S., Raso, A., Mueller, S., Nicolaides, T., Silva, K., Perbet, R., Vasiljevic, A., Faure Conter, C., Frappaz, D., Leary, S., Crane, C., Chan, A., Ng, H.-K., Shi, Z.-F., Mao, Y., Finch, E., Eisenstat, D., Wilson, B., Carret, A. S., Hauser, P., Sumerauer, D., Krskova, L., Larouche, V., Fleming, A., Zelcer, S., Jabado, N., Rutka, J. T., Dirks, P., Taylor, M. D., Chen, S., Bartels, U., Huang, A., Ellison, D. W., Bouffet, E., Hawkins, C., & Tabori, U.
Venue
Journal of Clinical Oncology
Published
2017-09-01
Volume
35
Issue
25
Pages
2934-2941
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2737907665
Cited by
349
References
28
FWCI
16.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. https://app.cochat.ai/papers/10.1200/jco.2016.71.8726
The paper
Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., Ling, C., McKeown, T., Loukides, J., Cruz, O., de Torres, C., Ho, C.-Y., Packer, R. J., Tatevossian, R., Qaddoumi, I., . . . Tabori, U. (2017). Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.71.8726

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.